NasdaqGS - Delayed Quote USD

Zynex, Inc. (ZYXI)

Compare
8.18 -0.01 (-0.12%)
At close: September 18 at 4:00 PM EDT
8.18 0.00 (0.00%)
After hours: September 18 at 4:00 PM EDT
Loading Chart for ZYXI
DELL
  • Previous Close 8.19
  • Open 8.27
  • Bid 8.14 x 100
  • Ask 8.22 x 200
  • Day's Range 8.10 - 8.44
  • 52 Week Range 7.04 - 13.77
  • Volume 96,811
  • Avg. Volume 150,626
  • Market Cap (intraday) 259.654M
  • Beta (5Y Monthly) 0.54
  • PE Ratio (TTM) 45.44
  • EPS (TTM) 0.18
  • Earnings Date Oct 24, 2024 - Oct 28, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jan 5, 2022
  • 1y Target Est 17.75

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

www.zynex.com

1,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ZYXI

View More

Performance Overview: ZYXI

Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ZYXI
24.89%
S&P 500
17.79%

1-Year Return

ZYXI
1.33%
S&P 500
26.24%

3-Year Return

ZYXI
27.74%
S&P 500
26.74%

5-Year Return

ZYXI
3.22%
S&P 500
86.92%

Compare To: ZYXI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZYXI

View More

Valuation Measures

Annual
As of 9/17/2024
  • Market Cap

    259.97M

  • Enterprise Value

    304.05M

  • Trailing P/E

    45.50

  • Forward P/E

    16.37

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.43

  • Price/Book (mrq)

    7.92

  • Enterprise Value/Revenue

    1.57

  • Enterprise Value/EBITDA

    20.42

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.12%

  • Return on Assets (ttm)

    4.80%

  • Return on Equity (ttm)

    12.70%

  • Revenue (ttm)

    193.61M

  • Net Income Avi to Common (ttm)

    6.04M

  • Diluted EPS (ttm)

    0.18

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    30.9M

  • Total Debt/Equity (mrq)

    228.46%

  • Levered Free Cash Flow (ttm)

    19.6M

Research Analysis: ZYXI

View More

Company Insights: ZYXI

Research Reports: ZYXI

View More

People Also Watch